Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Group Reports
80%
Secukinumab
80%
Evidence Review
80%
Psoriasis Treatment
50%
Randomized Controlled Trial
40%
Hidradenitis Suppurativa
40%
T Cell Subpopulations
40%
NTregs
40%
Natural Regulatory T Cells
40%
Demographic Factors
40%
During Pregnancy
40%
Young People
40%
Disease Process
40%
Regulatory T Cells
40%
Seasonal Changes
40%
High-throughput
40%
Vitamin D3 Supplementation
40%
Betamethasone
40%
Clinical Investigator
40%
Prognostic Factors
40%
T Helper 17 Cells (Th17)
40%
Single Technology Appraisal
40%
T Cells
40%
Effector T Cells
40%
Psoriasis
40%
Phototherapy
40%
Adalimumab
40%
Moderate-to-severe Psoriasis
40%
Acne Vulgaris
40%
Moderate to Severe
40%
Biomarker Research
40%
Molecular Biology
40%
Calcipotriol
40%
Translational Medicine
40%
Deucravacitinib
40%
Psoriasis in children
40%
Differential Effects
40%
Vitamin D
40%
Plaque Psoriasis
40%
Molecular Computer
40%
Treg
30%
Placebo
24%
NC16A
20%
Narrowband UVB
20%
Treg Subsets
20%
Th17 Subsets
20%
Treatment Modalities
20%
Th1-Th2
20%
Immune Markers
16%
Oral Biologics
16%
Immunology and Microbiology
T Cell
93%
Regulatory T Cell
90%
Interleukin 10
70%
Cell Population
40%
Bullous Pemphigoid
40%
Scanning Electron Microscopy
40%
Adalimumab
40%
CTLA-4
40%
Low Drug Dose
40%
Secukinumab
40%
Hidradenitis Suppurativa
40%
Peptides
40%
Epitope
40%
Cytokine
30%
Interleukin 4
30%
Immune Response
27%
Cytokine Response
27%
CD4
25%
Pemphigoid
20%
T Cell Proliferation
20%
Metabolite
20%
CD3 Antigen
20%
Inflammation
20%
Immunoglobulin E
20%
Th17 Cell
10%
Autoantibodies
10%
Upregulation
10%
Cytotoxic T Lymphocyte Antigen 4 Antibody
8%
Immunosuppressive Drug
8%
Normal Human
8%
Blood Level
8%
Secretion (Process)
8%
Immune Evasion
8%
Abatacept
8%
In Vitro
8%
Effector Cell
5%
Therapeutic Target
5%
Medicine and Dentistry
Topical Treatment
100%
Psoriasis
80%
Patient Compliance
40%
Acne Vulgaris
40%
Biological Marker
40%
Prospective Cohort Study
40%
Biological Therapy
40%
Pyoderma gangrenosum
40%
Acneiform Eruption
40%
Calcipotriol
40%
Phototherapy
32%
Oral
32%
Systemic Therapy
30%
Disease Process
20%
Prognostic Factor
20%
Translational Medicine
20%
Clinician
20%
Retinoid
20%
Patient Population
20%
Demographic Factor
20%
Patient Safety
20%
Adolescence
20%
Pharmacokinetics
20%
Decision Making
20%
Clinical Study
20%
Dermatology Life Quality Index
16%
Th17 Cell
16%
Betamethasone Dipropionate Plus Calcipotriol
16%
Recurrent Disease
13%
Ulcer
13%
Dermatology
8%
Cigarette Smoking
8%
Psoriasis Area and Severity Index
8%
Clobetasol Propionate
6%
Retrospective Cohort Study
6%
Quality of Life
6%
Base
6%
Hazard Ratio
6%
Topical Corticosteroid
6%
Tacrolimus
6%
Dermatosis
6%
Secondary Care
6%
Diseases
6%
Inflammation
6%
Side Effect
6%
